Dr. John Cush RheumNow
8 months 2 weeks ago
Beyond malignancy, look out for LICATS with CAR-T
CD19 chimeric antigen receptor (CAR) T cell therapy took the centre stage in 2022 where data pertaining to a successful case series of 5 patients with refractory SLE were published by Prof Schett’s group. Since then, this area https://t.co/JbTB033gti
Dr. John Cush RheumNow
8 months 2 weeks ago
GLP-1 Receptor Agonists in PsA: Mortality and MACE
Dr. Antoni Chan reports on abstract 0849 (Mortality and Major Adverse Cardiac Events (MACE) with GLP-1 Receptor Agonists in Psoriatic Arthritis), presented at #ACR25.
https://t.co/XNyt3UIjgp https://t.co/RUnZCjXF9T
Dr. John Cush RheumNow
8 months 2 weeks ago
Tocilizumab Beats Methotrexate in GCA
Dr. Mike Putman reports on abstract 0891 (MEthotrexate versus TOcilizumab for treatment of Giant cell Arteritis (METOGiA trial): a multicenter, randomized, controlled trial), presented at the #ACR25.
https://t.co/IeCWZGupqR https://t.co/SCF1guorMs
Dr. John Cush RheumNow
8 months 2 weeks ago
Putting Steroid Tapering into Practice in SLE
Drs. Yuz Yusof and Ed Vital discuss abstract 1526 (Guidance For Corticosteroid Tapering In Patients With Systemic Lupus Erythematosus: Results From An International Delphi Consensus Project) presented at #ACR25. https://t.co/nqMyy3qNto
Dr. Jack Cush reviews the journal articles, news and guidelines from this past week on RheumNow.com
Dr. John Cush RheumNow
8 months 2 weeks ago
Taking a closer look: B-Cell depletion beyond the blood
At #ACR25, we have seen an exciting wave of cellular and immune therapies reshaping the landscape of autoimmune disease treatment. Following the landmark case series by the Erlangen group, multiple cellular therapies have https://t.co/GIrPwlGKE2
Dr. John Cush RheumNow
8 months 2 weeks ago
Having #RA does not increase mortality in CA pts Rx w/ immune checkpoint inhibitors (ICI). 301 Veterans w/ RA & 2114 nonRA controls were compared: all-cause mortality was similar (HR 1.09; 0.94, 1.25). Most deaths from cancer (90% & 91%), but rarely from infection (<1%) https://t.co/gsXie6HpTu
Dr. John Cush RheumNow
8 months 2 weeks ago
SLE Prospect. Observational Study of 826 SLE pts over 3 yr for outcomes& IFN signature (IFNGS). 71% were IFNGS-high. IFNGS-high pts were younger. on GC w/ Hi SLEDAI-2K. SLEDAI-2K decreased over time, regardless of IFNGS. By 36mos, 45% had ≥1 flare; higher in IFNGS. https://t.co/c3zHT2GfR5
Dr. John Cush RheumNow
8 months 2 weeks ago
IL-1 Inhibition in CPPD
Controlled clinical trials in patients with calcium Pyrophosphate Deposition Disease (CPPD) are scant. Now a metanalysis provides evidence that anakinra, an interleukin-1 inhibitor, is a promising alternative for patients with acute CPPD flares. https://t.co/7RkE2i6sYY
Dr. John Cush RheumNow
8 months 2 weeks ago
DAHLIAS study - Nipocalimab in Sjögren's Disease
Nipocalimab, a neonatal Fc receptor blocker that reduces circulating IgG and autoantibodies, was shown to be effective in a phase 2 trial in patients with severe Sjögren's disease.
https://t.co/tpoh8YF0F1 https://t.co/jFB1RKOqDV
In a new study involving 402 U.S.-based primary care physicians, researchers from Northwestern University and the University of Sydney identified a “sweet spot” in clinical decision-making. By presenting just the right number of treatment alternatives in the electronic health record (EHR) system, physicians were more likely to choose a high-quality alternative rather than defaulting to the status quo.
A cohort study shows that hospitalized patients with dermatomyositis have higher in-hospital mortality in the presence of active rash, interstitial lung disease, and elevated neutrophil to lymphocyte ratio at admission.Dermatomyositis (DM) has significiant morbidity and mortality risks; but is this altered with DM patients who are hospitalized?
Dr. John Cush RheumNow
8 months 2 weeks ago
Robinson et al has published that Epstein-Barr virus infects and reprograms autoreactive B cells to drive the systemic autoimmune response in SLE https://t.co/vjpvILrJOt https://t.co/HepyZrYW5L
